Cardiovascular disease: risk assessment and reduction, including lipid modification

taking a statin and have a creatine kinase level less than 5 times the upper limit of normal, reassure them that their symptoms are unlikely to be due to the statin and explore other possible causes. [May 2023] 1.11.5 Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin. [May 2023] Increase in blood glucose or HbA1c 1.11.6 Do not stop statins because of an increase in blood glucose level or HbA1c. (See the recommendations on assessing for risk of diabetes mellitus in NICE's guideline on preventing type 2 diabetes.) [May 2023] Restarting statins 1.11.7 Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses. [May 2023] Annual medication review 1.11.8 Provide annual medication reviews for people on lipid-lowering treatment. [May 2023, amended December 2023] 1.11.9 Offer an annual full lipid profile to inform discussions about secondary prevention of CVD. [May 2023, amended December 2023] 1.11.10 Consider an annual full lipid profile to inform discussions about primary prevention of CVD. [May 2023, amended December 2023] 1.11.11 During the annual medication review: â€¢ discuss and encourage medicines adherence, if the shared decision is to
